Moreover, these studies suggested broad degrees of activity in thyroid cancer cell lines independent of BRAF V600E mutations due either to activity of the compounds at alternative targets or activation of RAF kinases by other oncogenes (or both). This evidence concerns the gene BRAF and thyroid gland carcinoma.